Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
Aerovate Therapeutics, Inc. (AVTE)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
AVTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVTE alerts
High impacting Aerovate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AVTE
News
- Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLCGlobeNewswire
- Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law FirmGlobeNewswire
- Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals [Yahoo! Finance]Yahoo! Finance
- Aerovate Therapeutics, Inc. (NASDAQ: AVTE) was downgraded by analysts at Evercore ISI from an "outperform" rating to an "inline" rating. They now have a $2.00 price target on the stock, down previously from $27.00.MarketBeat
- Aerovate Therapeutics, Inc. (NASDAQ: AVTE) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.MarketBeat
AVTE
Earnings
- 11/13/23 - Miss
AVTE
Sec Filings
- 6/20/24 - Form SC
- 6/20/24 - Form 4
- 6/13/24 - Form 144
- AVTE's page on the SEC website